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Abstract
We analyzed the cardiovascular toxicities related to the use of abiraterone and enzalutamide in prostate
cancer. We found that these agents are associated with an increased risk of all- and high-grade cardiac
toxicity as well as an increased risk of all- and high-grade hypertension. Follow-up for the onset of treatment-
related cardiovascular events should be considered in these patients treated with abiraterone and
enzalutamide.
Introduction: The cardiovascular toxicity related to abiraterone and enzalutamide has been previously studied by
our group. In this analysis, we aim to update our previous ﬁndings related to abiraterone and enzalutamide,
including the new available evidence, both in castration-resistant and hormone-sensitive prostate cancer.
Patients and Methods: Prospective studies were identiﬁed by searching the MEDLINE/PubMed, Cochrane Library,
and ASCO Meeting abstracts. Combined relative risks (RRs) and 95% conﬁdence intervals (CIs) were calculated
using ﬁxed- or random-effects methods. Results: We included 7 articles in this meta-analysis, covering a total of
8660 patients who were used to evaluate cardiovascular toxicity. The use of new hormonal agents was associated
with an increased risk of all-grade (RR, 1.36; 95% CI, 1.13-1.64; P ¼ .001) and high-grade (RR, 1.84; 95% CI,
1.21-2.80; P ¼ .004) cardiac toxicity. The use of new hormonal agents was also associated with an increased risk of
all-grade (RR, 1.98; 95% CI, 1.62-2.43; P ¼ .001) and high-grade (RR, 2.26; 95% CI, 1.84-2.77; P ¼ .004) hyper-
tension compared with the controls. Abiraterone was found to signiﬁcantly increase the risk of both cardiac toxicity
and hypertension, whereas enzalutamide signiﬁcantly increases only the risk of hypertension. No differences were
found based on the dose of prednisone used with abiraterone. The major limitation of this study is that data are
available only as aggregate, and no single-patient information could be analyzed. Conclusions: Abiraterone and
enzalutamide signiﬁcantly increase the incidence and RR of cardiovascular toxicity in patients affected by meta-
static prostate cancer. Follow-up for the onset of treatment-related cardiovascular events should therefore be
considered in these patients.
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Prostate cancer (PC) is the most frequently diagnosed cancer in
men, with 161,360 new cases and 26,730 deaths estimated to occur
in 2017 in the United States.1 Androgen deprivation therapy
(ADT) is a cornerstone for treating locally advanced and metastatic
disease. Recently, new hormonal agents able to prevent the synthesis
of the testosterone by the inhibition of the cytochrome CYP17 (ie,
abiraterone) or the intracellular binding (ie, enzalutamide) with the
androgen receptor have demonstrated to increase the survival of
patients with castration-resistant disease (CRPC) and, more lately,
also of patients with metastatic hormone-sensitive disease (HSPC),Clinical Genitourinary Cancer Month 2017 - 1
2 - Cli
Cardiovascular Effects of Abiraterone and Enzalutamidenaive to hormonal agents. Historically, ADT is the ﬁrst step for
medical treatment of PC and has been largely studied. ADT is
characterized by a wide spectrum of toxicities and among those,
cardiovascular toxicity is one of the most interesting with conﬂicting
evidences.2-5
On the other hand, new hormonal agents are characterized by a
favorable toxicity proﬁle, with ﬂuid retention, edema, hypokalemia,
and transaminase increases peculiar to abiraterone, and fatigue and
hot ﬂashes typical of enzalutamide.
The cardiovascular toxicity related to abiraterone and enzaluta-
mide has been previously studied by our group. We reported an
increased incidence for all-grade but not for high-grade cardiovas-
cular toxicity and the increase of both all- and high-grade hyper-
tension in CRPC patients treated with new hormonal agents
including abiraterone, enzalutamide, and orteronel.6
In this analysis, we aim to update our previous ﬁndings related to
abiraterone and enzalutamide, including the new available evidences
both in CRPC and in HSPC settings.
Materials and Methods
Deﬁnition of the Outcome
The objective of this analysis was to assess the incidence and
relative risk (RR) of cardiovascular toxicity in patients treated with
abiraterone and enzalutamide for PC. The cardiovascular toxicity
considered included both arterial hypertension and cardiovascular
toxicity. The latter was deﬁned as the onset of any adverse cardiac
event signs and symptoms.
For each trial, the abiraterone and enzalutamide  prednisone
group was considered to be the experimental arm and a placebo 
prednisone group the control. Both all-grade (grades 1-4) and high-
grade (grades 3-5) events were considered to be the main outcomes,
and the analysis was conducted in order to identify a signiﬁcant
difference between the 2 groups. A subgroup analysis was performed
to highlight any differences in terms of the incidence and RR of
cardiovascular toxicity between abiraterone and enzalutamide, and
in patients treated with abiraterone, a subgroup analysis was per-
formed based on the daily dose of prednisone used (ie, 10 vs. 5 mg).
Selection of the Studies
We reviewed MEDLINE/PubMed, the Cochrane Library, and
the American Society of Clinical Oncology (ASCO) University
Meeting abstracts for citations from 2013 to June 15, 2017. The
search criteria were limited to articles published in the English
language and phase III or phase II randomized controlled trials in
patients with PC. The MeSH terms used for the search of PubMed
and the Cochrane Library were “abiraterone” or “enzalutamide.”
For the search in the ASCO meeting library, we used the name of
the drugs and the terms “phase II” or “phase III”; the search was
limited from 2013 to 2017 and to ASCO annual conferences and
genitourinary cancer symposiums. The summaries for the product
characteristics were searched for at http://www.accessdata.fda.gov/
scripts/cder/drugsatfda/index.cfm. If more than one publication
was found for the same trial, the most recent, complete, and
updated version was included in the ﬁnal analysis.
Study quality was assessed using the Jadad 5-item scale, taking
into account randomization, double blinding and withdrawals. The
ﬁnal score ranged from 0 to 5.7nical Genitourinary Cancer Month 2017Data Extraction
Two authors (R.I. and C.C.) independently conducted the data
extraction according to the Preferred Reporting Items for Systematic
Review and Meta-Analysis (PRISMA) statement,8 and a consensus
approach was used to resolve any discrepancies. The data obtained
for each trial included the ﬁrst author’s name, year of publication,
trial phase, number of evaluable patients, number of arms, drugs
used in the experimental and control arms, dosage, median follow-
up, median treatment duration, and number of patients with any
cardiac event or hypertension.
Statistical Method
The calculation of incidence was performed from the data
available in each study. The proportion of patients who suffered
cardiovascular events and the derived 95% conﬁdence intervals
(CIs) were calculated for each study. We also calculated the RR and
CIs of events in patients assigned to treatment with new hormonal
agents compared with the controls in the same study. To calculate
the 95% CIs, the variance of a log-transformed study-speciﬁc RR
was derived using the delta method.9
Statistical heterogeneity between the trials included in the meta-
analysis was assessed using the Cochrane Q statistic, and inconsis-
tency was quantiﬁed with an I2 statistic {100%  [(Qdf)/Q]}.10
The assumption of homogeneity was considered to be invalid for
P values less than .1. Summary incidence and RRs were calculated
using random- or ﬁxed-effects models, depending on the hetero-
geneity of the included studies. When there was no substantial
heterogeneity, the pooled estimate that was calculated based on the
ﬁxed-effects model was reported using the inverse variance method.
When substantial heterogeneity was observed, the pooled estimate
that was calculated based on the random-effects model was reported
using the DerSimonian et al method,11 which considers both
within- and between-study variations.10 An indirect comparison
between the groups was performed using a c2 test. A 2-tailed P-
value of less than .05 was considered to be statistically signiﬁcant.
All the data were collated using Microsoft Ofﬁce Excel 2007. The
statistical analyses were performed using the RevMan software for
meta-analysis (v. 5.2.3).12
Results
Search Results
The electronic search revealed 2246 citations; after screening,
2035 records were eliminated because they did not match the
initial requirements (Figure 1). At the end of the review process,
7 articles were included in the qualitative and quantitative syn-
theses.13-19 Four studies compared abiraterone plus prednisone
over a placebo plus prednisone, whereas the remaining 3
compared enzalutamide over a placebo in 2 studies and enzalu-
tamide over bicalutamide in the last study. Five studies were
performed in patients with metastatic CRPC and 2 in patients
with metastatic HSPC. The characteristics of the studies are
shown in Table 1.
The studies included in this analysis covered a total of 8660
patients. Among them, 2878 patients were treated with abir-
aterone and 1854 with enzalutamide in the experimental arms,
whereas 3928 received a placebo  prednisone in the control
arms.
Figure 1 Flowchart of the Search Process
Roberto Iacovelli et alCardiac Toxicity
In the experimental arm, the incidence of all-grade cardiac events
was 11.7%, whereas in the control arm, it was 8.6%. Treatment
with new hormonal agents increased the risk of all-grade toxicity by
36% (random effect: RR, 1.36; 95% CI, 1.13-1.64; P ¼ .001).
There was signiﬁcant heterogeneity (c2, 11.7; P ¼ .07; I2, 49%).
The incidence of high-grades cardiac events was 3.7% in the
experimental arms and 2.0% in the control arms. Treatment with
new hormonal agents signiﬁcantly increased the risk of high-grades
cardiac toxicity (random effect, RR, 1.84; 95% CI, 1.21-2.80; P ¼
.004), signiﬁcant heterogeneity was found (c2, 13.3; P ¼ .04; I2,
56%) (Figure 2).
The incidence of all-grade and high-grade cardiac toxicity by the
abiraterone was 13.7% and 4.5%, respectively; these were signiﬁcantly
increased compared with placebo (RR, 1.41; 95% CI, 1.21-1.64; P <
.001 and RR, 2.22; 95% CI, 1.60-3.07; P < .001) (Table 2).
The incidence of all-grade and high-grade cardiac toxicity by the
enzalutamide was 8.6% and 2.5%, respectively; these were not
signiﬁcantly increased compared with placebo (RR, 1.25; 95% CI,
0.99-1.59; P ¼ .3 and RR, 1.28; 95% CI, 0.45-3.66; P ¼ .7)
(Table 2). No differences were found in the RR of both all-grade
(P ¼ .9) and high-grade (P ¼ .3) cardiac toxicity between abir-
aterone and enzalutamide.When studies performed in patients with HSPC were compared
with those performed in patients with CRPC, patients treated with
abiraterone with CRPC have signiﬁcant major incidence of high-
grade cardiac toxicity events compared with patients with HSPC,
but no increase of all-grades cardiac toxicity was found. The same
evidence was found for patients treated with placebo (see
Supplemental Table 1 in the online version).
Hypertension
In the experimental arms, the incidence of all-grade hypertension
was 19.6%, whereas in the control arms, it was 10.9%. Treatment
with new hormonal agents increased the risk of all-grade hypertension
by 98% (random effect, RR, 1.98; 95% CI, 1.62-2.43; P ¼ .001).
There was signiﬁcant heterogeneity (c2, 12.0; P ¼ .006; I2, 67%).
The incidence of high-grade hypertension was 6.1% in the
experimental arms and 3.1% in the control arms. Treatment with
new hormonal agents more than doubled the risk of high-grade
hypertension (ﬁxed effect, RR, 2.26; 95% CI, 1.84-2.77;
P < .001); no signiﬁcant heterogeneity was found (c2, 6.68;
P ¼ .35; I2, 10%) (Figure 3).
The incidence of all-grade and high-grade hypertension by the
abiraterone was 26.2% and 6.9%, respectively; these were signiﬁ-
cantly increased compared with placebo (RR, 1.79; 95% CI,Clinical Genitourinary Cancer Month 2017 - 3
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4 - Clinical Genitourinary Cancer Month 20171.45-2.21; P < .001 and RR, 2.19; 95% CI, 1.73-2.78; P < .001)
(Table 2).
The incidence of all-grade and high-grade hypertension by the
enzalutamide was 10.5% and 4.8%, respectively; these were
signiﬁcantly increased compared with placebo (RR, 2.66; 95% CI,
1.94-3.66; P < .001 and RR, 2.44; 95% CI, 1.64-3.63; P < .001)
(Table 2). A signiﬁcant difference was found in the RR for all-grade
(P ¼ .04) but not for high-grade (P ¼ .7) hypertension between
abiraterone and enzalutamide.
When studies performed in patients with HSPC were compared
with those performed in patients with CRPC, patients treated with
abiraterone for HSPC have major incidence of hypertension, but
the difference was not signiﬁcant. When the incidence of hyper-
tension was compared in patients treated with placebo, patients with
HSPC have a signiﬁcantly increased incidence of adverse events
compared with patients with CRPC (see Supplemental Table 2 in
the online version).
Role of Prednisone Dose
A total of 2267 patients received prednisone 10 mg daily, and
3107 patients received prednisone 5 mg daily; among these 2
groups, 1333 and 1545 received abiraterone.
In the experimental arms, the incidence of all-grade cardiac
toxicity was 18.9% and 9.2%, and in the control arms, 15.2% and
6.0%, when patients were treated with 10 mg or 5 mg of predni-
sone, respectively. No signiﬁcant difference (P ¼ .4) was found
between the RR of all-grade toxicity in patients treated with 10 mg
(RR, 1.33; 95% CI, 1.10-1.61; P ¼ .003) or 5 mg (RR, 1.54; 95%
CI, 1.20-1.97; P < .001).
In the experimental arms, the incidence of high-grade cardiac
toxicity was 6.5% and 2.8%, and in the control arms, the incidence
of high-grade cardiac toxicity was 3.4% and 1.1%, when patients
were treated with 10 mg or 5 mg of prednisone, respectively. No
signiﬁcant difference (P ¼ .5) was found between the RR of high-
grade toxicity in patients treated with 10 mg (RR, 2.06; 95% CI,
1.38-3.08; P < .001) or 5 mg (RR, 2.62; 95% CI, 1.50-4.56;
P < .001).
In the experimental arms, the incidence of all-grade hypertension
was 16.3% and 33.5%, and in the control arms, the incidence of all-
grade hypertension was 11.3% and 16.9%, when patients were
treated with 10 mg or 5 mg of prednisone, respectively. No
signiﬁcant difference (P ¼ .3) was found between the RR of all-
grades hypertension in patients treated with 10 mg (RR, 1.61;
95% CI, 1.30-2.00; P < .001) or 5 mg (RR, 1.94; 95% CI,
1.41-2.71; P < .001).
In the experimental arms, the incidence of high-grade hyper-
tension was 2.6% and 10.7%, and in the control arms, the
incidence of high-grade hypertension was 1.9% and 4.6%, when
patients were treated with 10 mg or 5 mg of prednisone, respec-
tively. No signiﬁcant difference (P ¼ .4) was found between the RR
of high-grade hypertension in patients treated with 10 mg (RR,
1.72; 95% CI, 0.97-3.06; P ¼ .06) or 5 mg (RR, 2.31; 95% CI,
1.78-3.01; P < .001).
Quality of the Studies
All the studies were randomized, double-blind clinical trials, with
the exception of the Systemic Therapy in Advancing or Metastatic
Figure 2 Relative Risk for All-grade (A) and High-grade (B) Cardiac Toxicity in Patients Treated With New Hormonal Agents or Control
Abbreviations: CI ¼ conﬁdence interval; df ¼ degrees of freedom.
Roberto Iacovelli et alProstate Cancer: Evaluation of Drug Efﬁcacy (STAMPEDE) trial,
which was an open label study. This last trial has 3 points in the
Jadad score, whereas all other studies have 5 points. The median
value of 4.7 points conﬁrms the good quality of studies included in
the analysis.
Discussion
To our knowledge, this is the largest up-to-date meta-analysis
investigating the incidence and the relative risk of cardiac toxicity and
hypertension in patients treated with abiraterone and enzalutamide
for PC. In a previous paper by our group, we reported a signiﬁcant
increase for all-grade cardiovascular toxicity but not for high-grade,
with differences from CYP-17 inhibitors and enzalutamide.6
In this paper, more than 8600 patients were included in the ﬁnal
analysis, and we are able to conﬁrm that new hormonal agents in-
crease the risk of a cardiac event by 36% compared with ADT and
the risk of high-grade toxicity by 84%, even if the incidence remains
low in less than 12% and 4% of patients, respectively. Our results
suggest that abiraterone signiﬁcantly increases the RR of cardio-
vascular toxicity, whereas enzalutamide does not.
Regarding the incidence of hypertension, we found that such new
hormonal therapies signiﬁcantly increase the risk for both all- and
high-grade hypertension, but this is more evident in patients treated
with enzalutamide. A signiﬁcant increase of the RR of all-grade
toxicity was found in patients treated with enzalutamide
compared with abiraterone.Interestingly, we can describe 2 classes of drugs, both acting on
the androgen axis and both used in patients with CRPC, which may
have different patterns of cardiovascular toxicity, with abiraterone
mainly generating cardiac events and enzalutamide primarily leading
to hypertension. This difference may help the clinician to choose
between the 2 agents.
Moreover, the increased incidence of cardiac toxicity in patients
treated for CRPC but not for HSPC suggests that the length of
therapy with abiraterone, longer in patients with HSPC, is not
directly related to the increased risk of cardiac events. These are
probably related to the longer duration of ADT in patients with
CRPC. The increased incidence of hypertension in HSPC is
probably related to the use of lower dose of prednisone in these trials
and to the increased risk of abiraterone-related toxicities.
Recently, 2 trials presented at ASCO 2017 conference tested the
addition or the sequence of new hormonal agents. A Phase 4,
Randomized, Double-blind, Placebo-controlled Study Of
Continued Enzalutamide Treatment Beyond Progression In Pa-
tients With Chemotherapy-naïve Metastatic Castration-resistant
Prostate Cancer (PLATO) trial investigated the addition of abir-
aterone or placebo to enzalutamide in patients with CRPC who
progressed to enzalutamide. This study reported that the incidence
of the high-grade hypertension was 9.6% in the combination arm
compared with 1.6% in the group of patients treated with placebo
and abiraterone.20 On the other hand, a phase II study that ran-
domized 202 patients to receive the sequence of abirateroneClinical Genitourinary Cancer Month 2017 - 5
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6 - Clinical Genitourinary Cancer Month 2017followed by enzalutamide (or vice versa) reported an increased
incidence of high-grade hypertension in patients treated with abir-
aterone compared with enzalutamide (21% vs. 12%).21 Both
studies conﬁrmed the cardiovascular toxicity of new hormonal
agents and their addictive effect.
In this paper, we also analyzed the role of prednisone in the
prevention of mineralocorticoid-related adverse events that arise
because of CYP17 inhibition with abiraterone. In phase I to II
trials, abiraterone acetate was administered without any gluco-
corticoid, and hypertension and hypokalemia were successfully
managed with the mineralocorticoid receptor antagonist epler-
enone.22-24 Considering that, the use of 5 mg prednisone twice
daily as a glucocorticoid replacement therapy was recommended.
On the other hand, glucocorticoid-related adverse events include
altered bone metabolism, immunosuppression, increased risk of
hyperglycemia and diabetes, adverse impact on mood and cogni-
tive function, and muscle weakness. Bearing in mind these events,
2 trials in metastatic HSPC have been designed with only 5 mg of
prednisone per day, and results were recently presented at ASCO
2017 conference.18,19 Both have been included in the meta-
analysis, and the incidence and RR of cardiovascular toxicity has
been compared with previous studies with abiraterone plus rec-
ommended dose of prednisone in patients with CRPC. Cardiac
toxicity was not increased in patients treated with a reduced dose
of prednisone. Despite that, an increased incidence of all-grade
(33.5% vs. 16.3%) and high-grade (10.7% vs. 2.6%) hyperten-
sion was found, but the difference in the RR was not signiﬁcant,
probably because a comparable increase of events was also found in
the control arms.
The evaluation of cardiovascular toxicity in this analysis must
also account for several factors. First, not all the patients had
previous therapy with ADT, and others could have several years of
exposition and continue this treatment during the administration
of new hormonal therapies. This analysis was also unable to
explore the effect of several other factors such as a patient’s medical
history, age, and other possible data that may be predictive of
cardiovascular toxicity. Moreover, the deﬁnition of cardiac toxicity
includes several diseases that cannot be standardized over the trials
included.
It is important to highlight that patients enrolled in clinical
studies generally had adequate organ function, and those with
chronic or concomitant disease were excluded. As a result of these
selection criteria, the incidence of cardiovascular events is expected
to be higher in the unselected population.
Despite these limitations, our analysis reported a signiﬁcant
increase of cardiac toxicity and hypertension in patients receiving
abiraterone or enzalutamide for PC.Considering that, patients should
be investigated for pre-existing risk factors in order to optimize those
who are modiﬁable, and there should be careful follow-up for the
onset of new treatment-related cardiovascular events.
Clinical Practice Points
 Abiraterone and enzalutamide are standard therapies for treat-
ment of metastatic PC. Cardiovascular toxicity has not been
well-addressed for these molecules.
 In this meta-analysis, we found that these 2 drugs increased the
risk of cardiac toxicity by 36% for all-grade and by 84% for high-
Figure 3 Relative Risk for All-grade (A) and High-grade (B) Hypertension in Patients Treated With New Hormonal Agents or Control
Abbreviations: CI ¼ conﬁdence interval; df ¼ degrees of freedom.
Roberto Iacovelli et algrade events. In addition, the risk of arterial hypertension was
increased by 100% for all-grade events and by 220% for high-
grade events.Disclosures
The authors have stated that they have no conﬂicts of interest.
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Supplemental Table 2 Incidence of Hypertension Based on
Type of Disease (ie, HSPC vs. CRPC)
Disease Incidence, % c2 P Value
High-grade hypertension
abiraterone
HSPC 10.7 71.78 >.05
CRPC 2.6
All-grade hypertension
abiraterone
HSPC 33.5 111.95 >.05
CRPC 16.3
High-grade hypertension
placebo
HSPC 4.6 12.10 <.001
CRPC 1.9
All-grade hypertension
placebo
HSPC 16.9 14.27 <.001
CRPC 11.3
Abbreviations: CPRC ¼ Castration-resistant prostate cancer; HSPC ¼ hormone-sensitive
prostate cancer.
Supplemental Table 1 Incidence of Cardiac Toxicity Based on
Type of Disease (ie, HSPC vs. CRPC)
Disease Incidence, % c2 P Value
High-grade cardiac toxicity
abiraterone
HSPC 2.85 21.55 <.001
CRPC 6.45
All-grade cardiac
toxicity abiraterone
HSPC 9.2 56.27 >.05
CRPC 19.9
High-grade cardiac toxicity
placebo
HSPC 1.09 16.60 <.001
CRPC 3.43
All-grade cardiac toxicity
placebo
HSPC 6.0 59.10 >.05
CRPC 15.2
Abbreviations: CPRC ¼ castration-resistant prostate cancer; HSPC ¼ hormone-sensitive
prostate cancer.
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